References
Key articles
Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020 Feb;158(3):693-702.Full text Abstract
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8.Full text Abstract
Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024 Sep 1;119(9):1730-53.Full text Abstract
Reference articles
1. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008 Jun;134(7):1842-60. Abstract
2. Brand SJ, Stone D. Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria. J Clin Invest. 1988 Sep;82(3):1059-66.Full text Abstract
3. Wu SV, Giraud A, Mogard M, et al. Effects of inhibition of gastric secretion on antral gastrin and somatostatin gene expression in rats. Am J Physiol. 1990 May;258(5 Pt 1):G788-93. Abstract
4. Manela FD, Ren J, Gao J, et al. Calcitonin gene-related peptide modulates acid-mediated regulation of somatostatin and gastrin release from rat antrum. Gastroenterology. 1995 Sep;109(3):701-6. Abstract
5. El-Zimaity H. Gastritis and gastric atrophy. Curr Opin Gastroenterol. 2008 Nov;24(6):682-6. Abstract
6. Sepulveda AR, Patil M. Practical approach to the pathologic diagnosis of gastritis. Arch Pathol Lab Med. 2008 Oct;132(10):1586-93. Abstract
7. Rugge M, Genta RM. Staging and grading of chronic gastritis. Hum Pathol. 2005 Mar;36(3):228-33. Abstract
8. Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology. 2021 Oct;161(4):1325-32.e7.Full text Abstract
9. Dixon MF, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol. 1996 Oct;20(10):1161-81. Abstract
10. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008 Aug;40(8):650-8. Abstract
11. Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011 Nov 7;17(41):4596-601.Full text Abstract
12. Rugge M, Genta RM, Fassan M, et al. OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018 Nov;113(11):1621-8. Abstract
13. Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol. 2006 Mar;4(3):306-14.Full text Abstract
14. Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010 Jun;71(7):1150-8. Abstract
15. Betesh AL, Santa Ana CA, Cole JA, et al. Is achlorhydria a cause of iron deficiency anemia? Am J Clin Nutr. 2015 Jul;102(1):9-19.Full text Abstract
16. Howard TA, Misra DN, Grove M, et al. Human gastric intrinsic factor expression is not restricted to parietal cells. J Anat. 1996 Oct;189 (Pt 2):303-13.Full text Abstract
17. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019 Sep;157(3):682-91;e2.Full text Abstract
18. Richards JB, Goltzman D. Proton-pump inhibitors: balancing the benefits and potential fracture risks. CMAJ. 2008 Aug 12;179(4):306-7.Full text Abstract
19. Yang YX, Lewis JD, Epstein S, et al. Long-term proton-pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. Abstract
20. Targownik LE, Lix LM, Metge CJ, et al. Use of proton-pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008 Aug 12;179(4):319-26.Full text Abstract
21. Phaosawasdi K, Sritunyarat Y, Lopimpisuth C, et al. Prevalence of achlorhydria in an Asian population detected using Congo red staining during routine gastroscopy: 22 years' experience from a single centre. BMJ Open Gastroenterol. 2022 Aug;9(1):e000976.Full text Abstract
22. Kuipers EJ, Pérez-Pérez GI, Meuwissen SG, et al. Helicobacter pylori and atrophic gastritis: importance of the cagA status. J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80. Abstract
23. Adamu MA, Weck MN, Gao L, et al. Incidence of chronic atrophic gastritis: systematic review and meta-analysis of follow-up studies. Eur J Epidemiol. 2010 Jul;25(7):439-48. Abstract
24. Weck MN, Stegmaier C, Rothenbacher D, et al. Epidemiology of chronic atrophic gastritis: population-based study among 9444 older adults from Germany. Aliment Pharmacol Ther. 2007 Sep 15;26(6):879-87. Abstract
25. Carmel R. Prevalence of undiagnosed pernicious anemia in the elderly. Arch Intern Med. 1996 May 27;156(10):1097-100. Abstract
26. Zhang Y, Weck MN, Schöttker B, et al. Gastric parietal cell antibodies, Helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in Germany. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):821-6.Full text Abstract
27. Toh BH, Alderuccio F. Pernicious anemia. Autoimmunity. 2004 Jun;37(4):357-61. Abstract
28. Davidson RJ, Atrah HI, Sewell HF. Longitudinal study of circulating gastric antibodies in pernicious anaemia. J Clin Pathol. 1989 Oct;42(10):1092-5.Full text Abstract
29. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002 Jul;16(7):1249-59.Full text Abstract
30. Venerito M, Varbanova M, Röhl FW, et al. Oxyntic gastric atrophy in Helicobacter pylori gastritis is distinct from autoimmune gastritis. J Clin Pathol. 2016 Aug;69(8):677-85. Abstract
31. Parsons BN, Ijaz UZ, D'Amore R, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017 Nov;13(11):e1006653.Full text Abstract
32. Argent RH, Thomas RJ, Aviles-Jimenez F, et al. Toxigenic Helicobacter pylori infection precedes gastric hypochlorhydria in cancer relatives, and H pylori virulence evolves in these families. Clin Cancer Res. 2008 Apr 1;14(7):2227-35. Abstract
33. Lewerin C, Jacobsson S, Lindstedt G, et al. Serum biomarkers for atrophic gastritis and antibodies against Helicobacter pylori in the elderly: implications for vitamin B12, folic acid, and iron status and response to oral vitamin therapy. Scand J Gastroenterol. 2008;43(9):1050-6. Abstract
34. D'Elios MM, Bergman MP, Azzurri A, et al. H+,K+-ATPase (proton-pump) is the target autoantigen of TH1-type cytotoxic T cells in autoimmune gastritis. Gastroenterology. 2001 Feb;120(2):377-86. Abstract
35. Claeys D, Faller G, Appelmelk BJ, et al. The gastric H+,K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology. 1998 Aug;115(2):340-7. Abstract
36. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003 Dec;98(12):2616-20. Abstract
37. Shi S, Klotz U. Proton-pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. Abstract
38. Fellenius E, Berglindh T, Sachs G. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+K+)ATPase. Nature. 1981 Mar 12;290(5802):159-61. Abstract
39. Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol. 2009 Feb;24(2):193-201. Abstract
40. Trieu JA, Bilal M, Saraireh H, et al. Update on the diagnosis and management of gastric intestinal metaplasia in the USA. Dig Dis Sci. 2019 May;64(5):1079-88. Abstract
41. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015 Apr;148(4):719-31;e3.Full text Abstract
42. Oh S, Kim N, Yoon H, et al. Risk factors of atrophic gastritis and intestinal metaplasia in first-degree relatives of gastric cancer patients compared with age-sex matched controls. J Cancer Prev. 2013 Jun;18(2):149-60.Full text Abstract
43. Tan MC, Mallepally N, Liu Y, et al. Demographic and lifestyle risk factors for gastric intestinal metaplasia among US veterans. Am J Gastroenterol. 2020 Mar;115(3):381-7. Abstract
44. Pittayanon R, Rerknimitr R, Klaikaew N, et al. The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up. Aliment Pharmacol Ther. 2017 Jul;46(1):40-5. Abstract
45. Laszkowska M, Oh A, Hur C. Screening for upper gastrointestinal malignancies in the United States - which immigrant groups should be considered high-risk? Gastroenterology. 2020 Jan;158(1):4-8.Full text Abstract
46. Graham DY, Alpert LC, Smith JL, et al. Iatrogenic Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol. 1988;83:192-9.
47. Saha A, Hammond CE, Trojanowska M, et al. Helicobacter pylori-induced H,K-ATPase alpha-subunit gene repression is mediated by NF-kappaB p50 homodimer promoter binding. Am J Physiol Gastrointest Liver Physiol. 2008 Mar;294(3):G795-807. Abstract
48. Kobayashi H, Kamiya S, Suzuki T, et al. The effect of Helicobacter pylori on gastric acid secretion by isolated parietal cells from a guinea pig: association with production of vacuolating toxin by H pylori. Scand J Gastroenterol. 1996 May;31(5):428-33. Abstract
49. Beales IL, Calam J. Inhibition of carbachol stimulated acid secretion by interleukin 1beta in rabbit parietal cells requires protein kinase C. Gut. 2001 Jun;48(6):782-9. Abstract
50. Liaskos C, Norman GL, Moulas A, et al. Prevalence of gastric parietal cell antibodies and intrinsic factor antibodies in primary biliary cirrhosis. Clin Chim Acta. 2010 Mar;411(5-6):411-5. Abstract
51. Kasperlik-Zaluska AA, Czarnocka B, Czech W, et al. Secondary adrenal insufficiency associated with autoimmune disorders: a report of twenty-five cases. Clin Endocrinol (Oxf). 1998 Dec;49(6):779-83. Abstract
52. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. Clin Endocrinol Metab. 2008 Feb;93(2):363-71. Abstract
53. Chan JC, Liu HS, Kho BC, et al. Pattern of thyroid autoimmunity in Chinese patients with pernicious anemia. Am J Med Sci. 2009 Jun;337(6):432-7. Abstract
54. Checchi S, Montanaro A, Ciuoli C, et al. Prevalence of parietal cell antibodies in a large cohort of patients with autoimmune thyroiditis. Thyroid. 2010 Dec;20(12):1385-9. Abstract
55. Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev. 2014 Apr-May;13(4-5):459-62. Abstract
56. Venerito M, Radünz M, Reschke K, et al. Autoimmune gastritis in autoimmune thyroid disease. Aliment Pharmacol Ther. 2015 Apr;41(7):686-93. Abstract
57. Karnes WE Jr, Samloff IM, Siurala M, et al. Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology. 1991 Jul;101(1):167-74. Abstract
58. Cover TL, Blaser MJ. Helicobacter in health and disease. Gastroenterology. 2009 May;136(6):1863-73. Abstract
59. Woo JS, el-Zimaity HM, Genta RM, et al. The best gastric site for obtaining a positive rapid urease test. Helicobacter. 1996 Dec;1(4):256-9. Abstract
60. Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori diagnosis and treatment. Gastroenterol Clin North Am. 2006 Jun;35(2):229-47. Abstract
61. Kokkola A, Sjöblom SM, Haapiainen R, et al. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol. 1998 Jan;33(1):88-92. Abstract
62. Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007 Apr;10(2):123-33. Abstract
63. Hutchinson C, Geissler CA, Powell JJ, et al. Proton-pump inhibitors suppress absorption of dietary non-haem iron in hereditary hemochromatosis. Gut. 2007 Sep;56(9):1291-5. Abstract
64. Sharma VR, Brannon MA, Carloss EA. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J. 2004 Sep;97(9):887-9. Abstract
65. Annibale B, Capurso G, Chistolini A, et al. Gastrointestinal causes of refractory iron deficiency anemia in patients without gastrointestinal symptoms. Am J Med. 2001 Oct 15;111(6):439-45. Abstract
66. Hershko C, Skikne B. Pathogenesis and management of iron deficiency anemia: emerging role of celiac disease, helicobacter pylori, and autoimmune gastritis. Semin Hematol. 2009 Oct;46(4):339-50. Abstract
67. Gupta S, Li D, El Serag HB, et al. AGA clinical practice guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020 Feb;158(3):693-702.Full text Abstract
68. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med. 1994 Aug 1;121(3):161-7. Abstract
69. McCloy RF, Arnold R, Bardhan KD, et al. Pathophysiological effects of long-term acid suppression in man. Dig Dis Sci. 1995 Feb;40(2 Suppl):96S-120S. Abstract
70. Hung PD, Schubert ML, Mihas AA. Zollinger-Ellison syndrome. Curr Treat Options Gastroenterol. 2003 Apr;6(2):163-70. Abstract
71. Helgadóttir H, Lund SH, Gizurarson S, et al. Predictors of gastrin elevation following proton pump inhibitor therapy. J Clin Gastroenterol. 2020 Mar;54(3):227-34.Full text Abstract
72. van Herwaarden MA, Samsom M, Smout AJ. 24-h recording of intragastric pH: technical aspects and clinical relevance. Scand J Gastroenterol Suppl. 1999;230:9-16. Abstract
73. Pounder RE, Fraser AG. Gastric acid secretion and intragastric acidity: measurement in health and disease. Baillieres Clin Gastroenterol. 1993 Mar;7(1):55-80. Abstract
74. Scott JM. Folate and vitamin B12. Proc Nutri Soc. 1999 May;58(2):441-8. Abstract
75. Den Elzen WP, Groeneveld Y, De Ruijter W, et al. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008 Mar 15;27(6):491-7. Abstract
76. Kowdley KV, Brown KE, Ahn J, et al. ACG clinical guideline: hereditary hemochromatosis. Am J Gastroenterol. 2019 Aug;114(8):1202-18.Full text Abstract
77. Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol. 2009 Nov 7;15(41):5121-8.Full text Abstract
78. Richter C, Tanaka T, Yada RY. Mechanism of activation of the gastric aspartic proteinases: pepsinogen, progastricsin and prochymosin. Biochem J. 1998 Nov 1;335 (Pt 3):481-90.Full text Abstract
79. Xu D, Fyfe JC. Cubilin expression and posttranslational modification in the canine gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G748-56. Abstract
80. Moestrup SK. New insights into carrier binding and epithelial uptake of the erythropoietic nutrients cobalamin and folate. Curr Opin Hematol. 2006 May;13(3):119-23. Abstract
81. Annibale B, Lahner E, Santucci A, et al. CagA and VacA are immunoblot markers of past Helicobacter pylori infection in atrophic body gastritis. Helicobacter. 2007 Feb;12(1):23-30. Abstract
82. Oh DS, Wang HS, Ohning GV, et al. Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison Syndrome. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1467-73. Abstract
83. Moore EW, Scarlata RW. The determination of gastric acidity by the glass electrode. Gastroenterology. 1965 Aug;49:178-88. Abstract
84. Eshmuratov A, Nah JC, Kim N, et al. The correlation of endoscopic and histological diagnosis of gastric atrophy. Dig Dis Sci. 2010 May;55(5):1364-75. Abstract
85. Al-Omari FA, Matalka II, Al-Jarrah MA, et al. An intelligent decision support system for quantitative assessment of gastric atrophy. J Clin Pathol. 2011 Apr;64(4):330-7. Abstract
86. Bettington M, Brown I. Autoimmune gastritis: novel clues to histological diagnosis. Pathology. 2013 Feb;45(2):145-9. Abstract
87. Graham DY, Rugge M, Genta RM. Diagnosis: gastric intestinal metaplasia - what to do next? Curr Opin Gastroenterol. 2019 Nov;35(6):535-43.Full text Abstract
88. Hwang YJ, Kim N, Lee HS, et al. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther. 2018 Feb;47(3):380-90. Abstract
89. Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018 Mar 22;378(12):1085-95.Full text Abstract
90. Malfertheiner P. Gastric atrophy reversible or irreversible after Helicobacter pylori eradication - an open question. Digestion. 2011;83(4):250-2.Full text Abstract
91. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8.Full text Abstract
92. Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024 Sep 1;119(9):1730-53.Full text Abstract
93. Elitsur Y, Tolia V, Gilger MA, et al. Urea breath test in children: the United States prospective, multicenter study. Helicobacter. 2009 Apr;14(2):134-40. Abstract
94. Shimoyama T, Oyama T, Matsuzaka M, et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey. Helicobacter. 2009 Apr;14(2):87-90. Abstract
95. Granstrom M, Lehours P, Bengtsson C, et al. Diagnosis of Helicobacter pylori. Helicobacter. 2008 Oct;13(suppl 1):7-12. Abstract
96. Stenstrom B, Mendis A, Marshall B. Helicobacter pylori - the latest in diagnosis and treatment. Aus Fam Physician. 2008 Aug;37(8):608-12. Abstract
97. Calvet X, Ramírez Lázaro MJ, Lehours P, et al. Diagnosis and epidemiology of Helicobacter pylori infection. Helicobacter. 2013 Sep;18(suppl 1):5-11.Full text Abstract
98. Ozturk E, Yesilova Z, Ilgan S, et al. Performance of acidified (14)C-urea capsule breath test during pantoprazole and ranitidine treatment. J Gastroenterol Hepatol. 2009;24:1248-51. Abstract
99. Kumar V. Pernicious anemia. MLO Med Lab Obs. 2007 Feb;39(2):28, 30-1. Abstract
100. Scalabrino G. Cobalamin (vitamin B12) in subacute combined degeneration and beyond: traditional interpretations and novel theories. Exp Neurol. 2005 Apr;192(2):463-79. Abstract
101. Holt PR. Intestinal malabsorption in the elderly. Dig Dis. 2007;25(2):144-50. Abstract
102. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007 Sep;102(9):2047-56;quiz 2057. Abstract
103. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005 Dec 21;294(23):2989-95. Abstract
104. Goel GA, Deshpande A, Lopez R, et al. Increased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppression. Clin Gastroenterol Hepatol. 2012 Apr;10(4):422-7.Full text Abstract
105. Zucker DK, Livingston RL, Nakra R, et al. B12 deficiency and psychiatric disorders: case report and literature review. Biol Psychiatry. 1981 Feb;16(2):197-205. Abstract
106. Graells J, Ojeda RM, Muniesa C, et al. Glossitis with linear lesions: an early sign of vitamin B12 deficiency. J Am Acad Dermatol. 2009 Mar;60(3):498-500. Abstract
107. Kumar G, Vaidyanathan L, Stead LG. Images in emergency medicine: koilonychia, or spoon-shaped nails, is generally associated with iron-deficiency anemia. Ann Emerg Med. 2007 Feb;49(2):243,250. Abstract
108. Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007 Feb;8(1):8-14. Abstract
109. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol. 2002 Jul;37(7):785-91. Abstract
110. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test: correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003 Aug;15(8):885-91. Abstract
111. Leja M, Kupcinskas L, Funka K, et al. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology. Dig Dis Sci. 2009 Nov;54(11):2377-84. Abstract
112. Antico A, Tampoia M, Villalta D, et al. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol. 2012;2012:520970.Full text Abstract
113. Agreus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scand J Gastroenterol. 2012 Feb;47(2):136-47.Full text Abstract
114. Loong TH, Soon NC, Nik Mahmud NRK, et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus. Biomed Rep. 2017 Nov;7(5):460-8.Full text Abstract
115. Tong Y, Wu Y, Song Z, et al. The potential value of serum pepsinogen for the diagnosis of atrophic gastritis among the health check-up populations in China: a diagnostic clinical research. BMC Gastroenterol. 2017 Jul 20;17(1):88.Full text Abstract
116. Bornschein J, Selgrad M, Wex T, et al. Serological assessment of gastric mucosal atrophy in gastric cancer. BMC Gastroenterol. 2012 Jan 31;12:10.Full text Abstract
117. Kikuchi S, Kato M, Katsuyama T, et al. Design and planned analyses of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter. 2006 Jun;11(3):147-51. Abstract
118. McNicholl AG, Forné M, Barrio J, et al. Accuracy of GastroPanel for the diagnosis of atrophic gastritis. Eur J Gastroenterol Hepatol. 2014;26:941-8.Full text Abstract
119. Lundell L, Vieth M, Gibson F, et al. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. Aliment Pharmacol Ther. 2015 Sep;42(6):649-63.Full text Abstract
120. Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019 Sep;68(9):1545-75.Full text Abstract
121. Dinis-Ribeiro M, Libânio D, Uchima H, et al. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG) and European Society of Pathology (ESP) guideline update 2025. Endoscopy. 2025 May;57(5):504-54.Full text Abstract
122. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353-1367.Full text Abstract
123. ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, et al. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc. 2015;82:1-8. Abstract
124. Toyokawa T, Suwaki K, Miyake Y, et al. Eradication of Helicobacter pylori infection improved gastric mucosal atrophy and prevented progression of intestinal metaplasia, especially in the elderly population: a long-term prospective cohort study. J Gastroenterol Hepatol. 2010 Mar;25(3):544-7. Abstract
125. De Vries AC, Kuipers EJ, Rauws EA. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol. 2009 Jun;104(6):1342-5. Abstract
126. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014 Feb;12(2):177-86;e3;discussion e12-3.Full text Abstract
127. National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Oct 2019 [internet publiction].Full text
128. Hunt RH, Scarpignato C. Potent acid suppression with PPIs and P-CABs: what's new? Curr Treat Options Gastroenterol. 2018 Dec;16(4):570-90. Abstract
129. Chey WD, Mégraud F, Laine L, et al. Vonoprazan triple and dual therapy for helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology. 2022 Sep;163(3):608-19.Full text Abstract
130. Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017 Jul;46(2):106-14. Abstract
131. Li M, Oshima T, Horikawa T, et al. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter. 2018 Aug;23(4):e12495. Abstract
132. Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-39.Full text Abstract
133. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019 Jul;157(1):44-53. Abstract
134. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, et al. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27. Abstract
135. Cummings LC, Hojat LS, Nguyen DC, et al. Tailored treatment based on helicobacter pylori genetic markers of resistance is associated with higher eradication success. Am J Gastroenterol. 2023 Feb 1;118(2):360-3.Full text Abstract
136. Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014 Oct;109(10):1595-602. Abstract
137. Stoffel NU, Cercamondi CI, Brittenham G, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-33. Abstract
138. Lahner E, Annibale B, Delle Fave G. Systemic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther. 2009 Feb 15;29(4):379-86. Abstract
139. Lahner E, Annibale B, Delle Fave G. Systemic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1219-29. Abstract
140. Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmac. 1991 Nov;32(5):569-72. Abstract
141. Soons PA, van den Berg G, Danhof M, et al. Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol. 1992;42(3):319-24. Abstract
142. Checchi S, Montanaro A, Pasqui L, et al. L-thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab. 2008 Feb;93(2):465-9. Abstract
143. Fishbane S, Ungureanu VD, Maeska JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis. 1996 Oct;28(4):529-34. Abstract
144. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999 Mar;33(3):464-70. Abstract
145. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008 Aug 19;149(4):242-50. Abstract
146. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997 Sep 4;337(10):670-6. Abstract
147. Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007 Aug 25;370(9588):657-66. Abstract
148. Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc. 2006 Apr;63(4):570-80. Abstract
149. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol. 2007;21(2):281-97. Abstract
150. Sjöblom SM, Sipponen P, Järvinen H. Gastroscopic follow up of pernicious anaemia patients. Gut. 1993 Jan;34(1):28-32. Abstract
151. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. N Engl J Med. 1997 Nov 13;337(20):1441-8. Abstract
Use of this content is subject to our disclaimer